VYNE Therapeutics (VYNE) EPS (Basic) Growth (3y) (2020 - 2025)
VYNE Therapeutics (VYNE) EPS (Basic) Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 53.55% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 37.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.29% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -2.89% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 86.43% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 86.43% |
| Mar 31, 2025 | -25.99% |
| Dec 31, 2024 | 94.48% |
| Jun 30, 2024 | 95.69% |
| Mar 31, 2024 | 96.25% |
| Dec 31, 2023 | 93.52% |
| Sep 30, 2023 | 75.48% |
| Jun 30, 2023 | 95.87% |
| Mar 31, 2023 | 96.44% |
| Dec 31, 2022 | 75.32% |
| Sep 30, 2022 | 82.60% |
| Jun 30, 2022 | 81.64% |
| Mar 31, 2022 | 28.12% |
| Dec 31, 2021 | 71.63% |
| Sep 30, 2021 | 60.75% |
| Jun 30, 2021 | 50.18% |
| Mar 31, 2021 | 59.03% |
| Dec 31, 2020 | 53.83% |
| Sep 30, 2020 | 54.33% |
| Jun 30, 2020 | -1.20% |